Mark R. Hake

Mark R. Hake

CFA

Mark R. Hake, CFA is a financial analyst and entrepreneur. He has been a Chartered Financial Analyst (CFA) for 31 years and has owned his own investment management and investment research firms that focused on value stocks, both in the U.S. and overseas.

Mark writes over 600 articles per year on stocks, cryptos, SPACs, convertibles, ETFs, and other financial securities. He has been ranked with 5 stars by TipRanks.com (under “Mark R. Hake”) with an average return of over 22% annually and #36 out of 8,116 writers. Presently he authors articles on Medium.com and other sites.

Mark also invests in public and private equities and has acted as a hedge fund manager and portfolio manager for various money management firms. He has also acted as CFO and Chief Strategy Officer for several fin-tech and software companies.

You can follow Mark on LinkedIn and on TipRanks.

Recent Articles

Growth in Crypto Trading Will Push Coinbase Stock Higher

By Mark R. Hake, CFA

Coinbase's growth trajectory in crypto trading will push the stock higher. COIN stock is worth at least $345.15, or one-third higher than today, assuming its growth trajectory continues.

Why Holo Could Easily Soar Over 100% to Its Previous Highs This Year

By Mark R. Hake, CFA

Holo crypto is likely to remain hot through the end of the year. It could easily reach its previous highs, up over 100% from here.

Nio Stock Is Still Undervalued, Just Not As Much As Before

By Mark R. Hake, CFA

According to my calculations, NIO stock is worth $38.58, 15% higher than Friday's close, given the delivery and revenue outlook from Nio.

Litecoin Is a Viable Altcoin With Potential for Strong Upside

By Mark R. Hake, CFA

Litecoin is a viable altcoin that has a good upside opportunity. Litecoin has a chance of rising over time as its popularity grows.

Cardano Should Outperform Ethereum by the End of the Year

By Mark R. Hake, CFA

Cardano should outperform Ethereum over the next year. Cardano has a number of benefits over Ethereum, which could push ADA by the end of 2021.

Bionano Genomics Just Can’t Kick the Cash-Raising Bug With All Its Dilution

By Mark R. Hake, CFA

Bionano Genomics can't kick the cash-raising bug. BNGO stock could fall to $1.85, its potential cash per share if it continues to raise cash.

High Cash Burn Will Push Vaxart Stock Down To $1 Per Share

By Mark R. Hake, CFA

Vaxart stock is likely headed down 85% towards its cash per share. VXRT stock is not worth much more than $1.00 per share, so expect to see it drop 85%.

Tons of Cash On Hand Won’t Save Sundial Growers From Falling Further

By Mark R. Hake, CFA

Despite a large cash balance Sundial Growers stock is set to fall further. SNDL stock could fall to just 33 cents, or 53% lower, at its cash per share balance.

Clover Stock Is Stuck In a Dryer Tumble of Losses and More Losses

By Mark R. Hake, CFA

Clover stock is stuck in a dryer tumble of losses and more Losses. CLOV stock will fall if the company does not produce Q1 numbers on May 17 that imply full year 24% growth.

UWM Holdings Looks Like a Value Bargain With Low PE and Attractive Yield

By Mark R. Hake, CFA

UWM Holdings looks like a value bargain with a low PE and attractive yield. UWMC stock is worth $10 per share, 36% over its recent price at 8 times forward EPS.

Load More